Woodline Partners LP Syndax Pharmaceuticals Inc Transaction History
Woodline Partners LP
- $13.5 Billion
- Q4 2024
A detailed history of Woodline Partners LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Woodline Partners LP holds 1,891,803 shares of SNDX stock, worth $25.4 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
1,891,803
Previous 1,896,032
0.22%
Holding current value
$25.4 Million
Previous $36.5 Million
31.48%
% of portfolio
0.19%
Previous 0.33%
Shares
14 transactions
Others Institutions Holding SNDX
# of Institutions
232Shares Held
92.7MCall Options Held
1.39MPut Options Held
543K-
Kynam Capital Management, LP Princeton, NJ8.52MShares$115 Million7.14% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$106 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.95MShares$80 Million0.01% of portfolio
-
Morgan Stanley New York, NY5.31MShares$71.4 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$65.6 Million0.0% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $760M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...